Prescribing information

 

   

MF is a rare, life-limiting blood cancer with debilitating symptoms1–3

MF is now recognised as a life-threatening blood cancer with a 5-year survival of 38.9%, meaning it lags behind other blood cancers such as myeloma (52.2%), ALL (68.6%) and CLL (85.1%).1,2,4

Patients with MF face increasingly debilitating symptoms as the disease progresses.*1,3 Over the course of 1 year, patients can experience:*3

 Icons showing the variety of symptoms MF patients can experience over the course of 1 year

 

MF requires regular symptom monitoring for guiding informed treatment decisions and identifying eligible patients for therapy,5,6 yet findings from the TRACK Survey found that half of physicians do not monitor changes with an assessment tool.†7

 

In addition, findings from the REALISM UK study showed that nearly half of MF patients with symptomatic disease (classification of intermediate-2 or high-risk disease) fail to receive active management following diagnosis.‡8

Blue shape with the words 'Patients require treatment to prevent MF symptoms worsening.9 View the BSH guidelines for treatment of MF, and treat those eligible as early as possible to change the lives of your patients with MF.'

Footnotes

The TRACK Survey assessed how BSH guidelines from 2012 on the diagnosis and management of MPNs are being interpreted and implemented across the UK (N=42). Select consultant haematologists across the UK were surveyed between September and October 2018.7

REALISM UK was a retrospective, multi-centre, non-interventional real-world evidence study to review the current treatment pathways for MF from across the United Kingdom, in 15 UK secondary care centres (N=200). Eligible patients were those aged ≥18 years at diagnosis of MF, with diagnosis >6 months and ≤5 years prior to data collection and with ≥1 follow-up visits.8

* Data from patients with MF (n=207) surveyed in the MPN Landmark Survey (N=813).3
† Data from consultant haematologists surveyed in the TRACK Survey (N=42).7
‡ Watch and wait as choice of first management strategy among IPSS intermediate-2 and IPSS high was seen in 49% and 46% of patients, respectively.8

 

Abbreviations

ALL, acute lymphoblastic leukaemia; BSH, British Society for Haematology; CLL, chronic lymphocytic leukaemia; IPSS, International Prognostic Scoring System; MF, myelofibrosis; MPN, myeloproliferative neoplasms; QoL, quality of life.

 

References

  1. Vannucchi AM, et al. Haematologica. 2015;100:1139–1145.
  2. Brunner AM, et al. Leuk Lymph. 2016;57:1197–1200.
  3. Mesa R, et al. BMC Cancer. 2016;16:167.
  4. National Cancer Institute. Cancer stat facts. Available at: http://seer.cancer.gov/statfacts/. Last accessed April 2020.
  5. Reilly J, et al. Br J Haematol. 2014;167:418–438.
  6. Scottish Medicines Consortium. Available at: https://www.scottishmedicines.org.uk/media/2277/ruxolitinib_jakavi_final_february_2015_for_website.pdf.Last accessed April 2020.
  7. Harrison C, et al. BSH 2019, 1–3 April; Glasgow, Scotland. Poster 178.
  8. Mead A, et al. ASH 2019, 7–10 December; Florida, USA. Poster P-1671.
  9. Verstovsek S, et al. N Engl J Med. 2012;366:799–807.
HCP20-C025 June 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]